{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:14:08Z","timestamp":1793747648762,"version":"4.6.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To study the real-world outcomes of intravitreal faricimab (IVF) in long-standing neovascular age-related macular degeneration (nAMD) over a 1-year study period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective single-center cohort study of patients with previously treated nAMD receiving IVF with at least 12 months of follow-up. Main outcome measures include injection intervals, visual acuity (VA), and optical coherence tomography features.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 263 eyes from 217 patients received 6.4 \u00b1 2.3 IVF injections over 1 year. Injection interval increased after switching to IVF (5.9 \u00b1 1.8 vs. 7.6 \u00b1 2.4 weeks) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). There was no improvement in VA after switching to IVF at any time period (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.15). Average CST decreased after the first IVF injection and was sustained for 1 year (313.7 \u00b1 96.0 vs. 288.2 \u00b1 80.6 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). There was a statistically significant resolution of subretinal fluid but not IRF at all time points (40.8%\u201350.4%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). Persistent fluid after the first IVF injection was resolved in 34.4% (n = 45) by 1 year. IVF was discontinued in 31 eyes (11.8%), four (1.6%) that experienced intraocular inflammation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Long-standing nAMD eyes switched to IVF experienced a significant extension in injection interval, stable visual acuity, improvement in CST, and resolution of fluid on OCT in many patients over 1 year.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004322","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:00:14Z","timestamp":1731445214000},"page":"446-453","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["REAL-WORLD LONG-TERM OUTCOMES OF INTRAVITREAL FARICIMAB IN PREVIOUSLY TREATED CHRONIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"45","author":[{"given":"Naveen R.","family":"Ambati","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio; and"},{"name":"Cincinnati Eye Institute, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio; and"},{"name":"Cincinnati Eye Institute, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brill","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio; and"},{"name":"Cincinnati Eye Institute, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Sisk","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio; and"},{"name":"Cincinnati Eye Institute, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"R1-20250226","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-20250226","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R3-20250226","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-20250226","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R5-20250226","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"R6-20250226","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/13543784.2019.1667333","article-title":"Tie-2\/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease","volume":"28","author":"Hussain","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"R7-20250226","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"R8-20250226","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","article-title":"Vascular-specific growth factors and blood vessel formation","volume":"407","author":"Yancopoulos","year":"2000","journal-title":"Nature"},{"key":"R9-20250226","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"R10-20250226","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"R12-20250226","first-page":"2218","article-title":"FARETINA-AMD- early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an IRIS RegistryTM analysis","volume":"64","author":"Borkar","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20250226","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (London)"},{"key":"R15-20250226","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"R16-20250226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration","volume":"262","author":"Kataoka","year":"2024","journal-title":"Graefes Archive Clin Exp Ophthalmol"},{"key":"R18-20250226","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short term outcomes of faricimab in patients with neovascular age related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R19-20250226","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S409822","article-title":"Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration","volume":"17","author":"Leung","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"R20-20250226","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R21-20250226","first-page":"e40100","article-title":"Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration","volume":"15","author":"Cheng","year":"2023","journal-title":"Cureus"},{"key":"R22-20250226","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.3390\/jcm12155145","article-title":"Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration","volume":"12","author":"Kishi","year":"2023","journal-title":"J Clin Med"},{"key":"R23-20250226","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-024-00537-5","article-title":"Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study","volume":"10","author":"Kanadani","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"R24-20250226","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","article-title":"Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review","volume":"67","author":"Madjedi","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"R25-20250226","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/IAE.0000000000001637","article-title":"Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained","volume":"38","author":"Lee","year":"2018","journal-title":"Retina"},{"key":"R26-20250226","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00417-015-3084-1","article-title":"Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice","volume":"254","author":"Despreaux","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T13:01:20Z","timestamp":1740574880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004322","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]}}}